Exploring the Transformative Power of AI in Drug Discovery: A report by S&P Global

AI is revolutionizing the pharmaceutical industry, offering unprecedented potential to reshape the healthcare landscape. Join us for an in-depth look at ‘AI In Pharmaceuticals: Promises of Innovation, Speed, and Savings,’ the latest research report by S&P Global Ratings. This report sheds light on the current state of AI in pharma and drug discovery, the challenges ahead, and the innovations driving the industry forward.  

In this special session, we’ll dive into the report’s fascinating findings with its authors:

• Ihsane Mesrar, Associate Healthcare Director, S&P Global Ratings
• Sudeep Kesh, Chief Innovation Officer, S&P Global Ratings
• Guillaume Benoit, Associate Healthcare Director, S&P Global Ratings 

Don't miss this opportunity to hear their insights and get answers to your questions on how AI is shaping the future of healthcare.

Some of the main topics in this interview include:

• The general overview of your report, "AI In Pharmaceuticals Promises Innovation," and the key takeaways for the pharmaceutical industry.
• Where do we currently stand in the use of AI in the pharmaceutical industry, and what are your projections for its impact over the next 5 and 10 years?
• What are the trends in AI adoption within the pharmaceutical sector, and how do you see the market evolving for AI applications?  
• How do you see AI affecting this process? What are the expectations of pharmaceutical companies and AI firms in terms of cost and time reduction?
• You mention large pharmaceutical companies are heavily investing in AI. How do you see these investments shaping the competitive landscape between big pharma and smaller AI-driven biotech companies? 

Key Takeaways from the S&P Global Report:

• Generative AI will transform pharmaceutical research and development by strengthening innovation, offering cost efficiencies, and speeding the traditionally ponderous research-to-market cycle.
• Large pharmaceuticals companies' significant investments in AI could establish enduring competitive advantages over smaller rivals.
• The benefits of AI will likely take years to filter through to treatments (and pharmaceutical company revenues) and remain dependent on further investment, regulatory evolution, and effective change management.